Liquid biopsies are rapidly gaining traction and becoming a standard of care for cancer. They are an attractive alternative to invasive, painful, costly tissue biopsies and can facilitate real-time monitoring while providing insight into the disease state, even for tissues that are difficult to access, such as brain cancers.
Circulating tumor cells (CTCs) offer several advantages or are complementary to other biomarkers in liquid biopsies. CTCs can be analyzed in their entirety, revealing key insights about targetable receptors and tumor heterogeneity and mutations. CTC concentration is also a corollary of disease progression and related to a patient’s response to therapy. The potential of CTCs had previously gone untapped because of the lack of technology to efficiently capture and characterize these cells.
Download this whitepaper to learn more about:
- How CTCs are an effective biomarker for translational research
- How sensitive, versatile CTC capture and recover technology can maximize your research
- How Celselect Slides overcome many limitations of current CTC approaches
